Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nabriva Therapeutics AG - ADR    NBRV

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
11.15(c) 11(c) 11.06(c) 11.15(c) 10.8(c) Last
16 919 28 512 6 660 3 209 450 Volume
-3.04% -1.35% +0.55% +0.81% -3.14% Change
More quotes
Financials ($)
Sales 2017 3,96 M
EBIT 2017 -62,3 M
Net income 2017 -64,8 M
Finance 2017 103 M
Yield 2017 -
Sales 2018 4,21 M
EBIT 2018 -76,5 M
Net income 2018 -79,6 M
Finance 2018 25,8 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 32,2x
EV / Sales2018 48,5x
Capitalization 230 M
More Financials
Company
Nabriva Therapeutics AG is a clinical-stage biopharmaceutical company.It engages in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics.The company was founded by Rodger Novak in October 2005 and is headquartered in... 
More about the company
Surperformance© ratings of Nabriva Therapeutics AG -
Trading Rating : Investor Rating :
More Ratings
Latest news on NABRIVA THERAPEUTICS AG -
03/25 NABRIVA THERAPEUTICS : Provides Business and Development Update and Reports 2016..
03/24 NABRIVA THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
03/24 NABRIVA THERAPEUTICS AG : Results of Operations and Financial Condition, Financi..
03/24 Nabriva Therapeutics Provides Business and Development Update and Reports 201..
02/27 Nabriva Therapeutics to Present at the Cowen and Company 37th Annual Healthca..
02/15 NABRIVA THERAPEUTICS AG : Regulation FD Disclosure, Financial Statements and Exh..
02/13 NABRIVA THERAPEUTICS AG : Change in Directors or Principal Officers (form 8-K)
02/08 Nabriva Therapeutics to Participate in Two Investor Conferences in February
02/03 NABRIVA THERAPEUTICS : Confirms No Sample Size Adjustment Required for LEAP 1 Ph..
02/02 Nabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 P..
More news
Sector news : Biotechnology & Medical Research - NEC
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
03/24 Nabriva Therapeutics reports FY results
02/26 WEEK IN REVIEW : BioSense Signs $68 Million China Deal With Neovacs For Therapeu..
02/17 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
01/27 BIOTECH FORUM DAILY DIGEST : Merger And Acquisition Activity Continues To Pick U..
2016 Midday Gainers / Losers
Advertisement
Chart NABRIVA THERAPEUTICS AG -
Duration : Period :
Nabriva Therapeutics AG -  Technical Analysis Chart | NBRV | US62957M1045 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 17,0 $
Spread / Average Target 57%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Colin Broom Chief Executive Officer
Daniel D. Burgess Chairman-Supervisory Board
Gary L. Sender Chief Financial Officer
Elyse G. Seltzer Chief Medical Officer
Thomas Lembck Chief Information Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NABRIVA THERAPEUTICS A..81.21%230
INCYTE CORPORATION39.26%28 461
QUINTILES IMS HOLDINGS..2.55%18 400
LONZA GROUP AG3.40%10 646
CELLTRION, INC.--.--%9 851
SEATTLE GENETICS, INC.20.69%9 075
More Results